FDA Approves Eloctate – first Antihemophilic Factor, Fc Fusion Protein for Patients with Hemophilia A

June 6, 2014 — The U.S. Food and Drug Administration today approved Eloctate, Antihemophilic Factor (Recombinant), Fc fusion protein, for use in adults and children who have Hemophilia A. Eloctate is the first Hemophilia A treatment designed to…
Drugs.com – New Drug Approvals

Pharmaceutical Stocks

[stock-ticker]

© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us